Zai Lab (ZLAB) said Monday that a phase 3 clinical trial evaluating first-line bemarituzumab plus chemotherapy for the treatment of gastric cancer met its primary endpoint of overall survival at an interim analysis.
The biopharmaceutical company said the treatment combination demonstrated a "statistically significant and clinically meaningful" improvement in overall survival compared with placebo plus chemotherapy.
Zai Lab also said that a phase 3 trial of bemarituzumab plus chemotherapy and nivolumab is ongoing and that data readout is expected in H2.
Shares of Zai Lab were up 2.1% in recent early trading.
Price: 35.46, Change: +0.71, Percent Change: +2.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.